Brief: Theranexus Cash Position Of 15.8 Million Euros At 30 Sept.
Nov 9 (Reuters) - THERANEXUS SA ALTHX.PA :
* CASH POSITION AT SEPT 30 AT EUR 15.8 MILLION
* THN101 WILL BE ENTERING PHASE II IN PATIENTS WITH
NEUROPATHIC
PAIN IN THE FIRST HALF OF 2019 - CEO
* THN102, WHICH TARGETS TWO INDICATIONS, BEGAN ITS PHASE II
TRIAL
FOR PATIENTS SUFFERING FROM EXCESSIVE DAYTIME SLEEPINESS (EDS)
ASSOCIATED WITH PARKINSON'S DISEASE - CEO
Source text for Eikon: ID:nACT55914
Further company coverage: ALTHX.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Thx Pharma SA
See all newsBrief: Theranexus And BBDF Announce Final And Positive Safety And Efficacy Data In The Phase I/II Trial Testing Batten-1
Brief: Theranexus End-Dec Total Available Funds Stood At EUR 4.9 Mln
Brief: Theranexus Declares Encouraging Prelim Results For Batten Disease Drug
Brief: Theranexus And BBDF Granted Positive Opinion By EMA For Design Of Batten-1 Phase III Trial
Brief: Theranexus And BBDF Win FDA Approval On Endpoints For Phase III Trial To Evaluate Batten-1 In CLN3 Batten Disease